Peptides, hormones and menopause
Menopause and hormone therapy, the 2025 label change, non-hormonal hot flash drugs, testosterone in women, GLP-1 drugs in midlife and bone health.
7 min read · By the Drawline team · Reviewed
Menopause changes hormones, weight, sleep and bone, and it is when many women first look at hormone therapy, GLP-1 drugs or peptides. These are the questions that come up most, answered from product labels, FDA and medical sources. Your clinician can tell you how they apply to you.
What is menopause, and when does it happen?
Menopause is the point when you have gone 12 months in a row without a period. It usually happens between ages 45 and 55. The years before it, called perimenopause, often bring irregular periods, hot flashes, night sweats, poor sleep and mood changes. Surgery that removes both ovaries, and some cancer treatments, can bring it on earlier.
What does hormone therapy treat?
Estrogen products are FDA-approved to treat moderate to severe hot flashes and night sweats, to treat vaginal dryness and pain with sex, and to prevent bone loss after menopause. A woman who still has a uterus takes a progestogen with estrogen, because estrogen alone raises the risk of cancer of the uterine lining (endometrial cancer). Low-dose vaginal estrogen works mainly where it is applied. The right product, route and length of treatment are decisions for you and your clinician.
What changed on hormone therapy labels in 2025?
In November 2025, FDA announced that it was removing the boxed warning about heart disease, breast cancer and probable dementia from menopausal hormone therapy labels. Information on those risks stays in the label outside the box. FDA kept one boxed warning: the risk of endometrial cancer when estrogen is taken alone, without a progestogen, by a woman who has a uterus. Labels are being updated product by product, so read the current label of yours. Risks such as blood clots and stroke still depend on age, time since menopause, the type of hormone and how it is taken.
Are there non-hormonal options for hot flashes?
Yes. Two prescription drugs approved for moderate to severe hot flashes from menopause work on brain signals rather than hormones:
- Fezolinetant (Veozah), approved in 2023. In December 2024 FDA added a boxed warning for rare but serious liver injury, with liver blood tests before starting and during the first months.
- Elinzanetant (Lynkuet), approved in October 2025. Its label warns about drowsiness and slowed thinking, and calls for liver tests before starting and after three months.
Neither is in a Drawline profile yet. Ask your clinician whether either fits you.
Is testosterone approved for women after menopause?
No testosterone product is FDA-approved for women in the United States. An international consensus statement from medical societies supports considering it only for low sexual desire that causes distress after menopause, keeping levels within the normal female range, under a clinician’s care. It does not support testosterone for energy, mood, bone or muscle in women. Products made for men are not designed for women.
Do GLP-1 drugs work differently around menopause?
The approvals for semaglutide and tirzepatide do not depend on menopause status, and the large trials included many women in midlife. Weight often rises around menopause while muscle and bone slowly decline with age. Part of the weight lost on a GLP-1 drug is lean mass, not fat, so protein intake and resistance exercise are worth discussing with your clinician. The protein calculator shows published ranges.
What about bone health?
Bone loss speeds up in the years after menopause. The U.S. Preventive Services Task Force recommends a bone density scan (DXA) for women aged 65 and older, and for younger women after menopause whose risk is raised, for example by low body weight, smoking, heavy drinking or a parent who broke a hip. Rapid weight loss can also lower bone density, which is one more reason to raise bone health with your clinician if you are losing weight.
Do research peptides help with menopause symptoms?
There is no good human evidence that research peptides such as BPC-157, CJC-1295 or MOTS-c treat hot flashes, sleep problems, bone loss or other menopause symptoms. They are not FDA-approved, and their quality and contents are not checked the way prescription medicines are. See how to grade the evidence behind a claim.
What should I ask my clinician?
- Which treatments fit my symptoms, age and health history, and what are the risks for me?
- Do I need a progestogen with estrogen?
- Should I have a bone density scan, and which bloodwork makes sense?
- How do my other medicines and anything I am considering, including peptides, fit with this?
The Drawline report for your doctor lists your vials, doses, side effects and bloodwork. See also the guide on talking to your doctor about peptides.
Sources: NICHD (NIH): Menopause; FDA: HHS removes misleading warnings on hormone replacement therapy (November 2025); FDA: Warning about rare but serious liver injury with Veozah (fezolinetant); FDA: Drug Trials Snapshots, Lynkuet (elinzanetant); Global consensus position statement on the use of testosterone therapy for women (2019); Wilding et al., semaglutide in adults with overweight or obesity (STEP 1), NEJM 2021; U.S. Preventive Services Task Force: Screening for osteoporosis (2025).
This guide is for research and educational use. It is not medical advice. Confirm anything that affects your health with a licensed professional.
Spot a mistake or an out-of-date fact? Report an error. We check every report against the sources.